Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Abstract Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough therapies for type 2 diabetes mellitus (T2DM). In this review article, we discuss the mechanistic and clinical s...

Full description

Bibliographic Details
Main Authors:	Pierre Gourdy, Patrice Darmon, François Dievart, Jean-Michel Halimi, Bruno Guerci
Format:	Article
Language:	English
Published:	BMC 2023-04-01
Series:	Cardiovascular Diabetology
Subjects:	Glucagon-like peptide-1 receptor agonists Sodium-glucose cotransporter-2 inhibitors Type 2 diabetes mellitus Combination therapy Cardiovascular protection
Online Access:	https://doi.org/10.1186/s12933-023-01798-4

Similar Items

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
by: Lixin Du, et al.
Published: (2022-10-01)

The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
by: M. B. Antsiferov, et al.
Published: (2023-05-01)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
by: Katarzyna Wołos-Kłosowicz, et al.
Published: (2022-10-01)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
by: Marta Baviera, et al.
Published: (2022-08-01)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
by: Soraya Puglisi, et al.
Published: (2021-10-01)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
by: Agata Winiarska, et al.
Published: (2021-10-01)

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023-12-01)

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
by: Filippo Trombara, et al.
Published: (2023-02-01)

First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis
by: Rui Deng, et al.
Published: (2024-01-01)

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
by: Yasuo Terauchi, et al.
Published: (2019-11-01)

The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study
by: Ghazwa B. Korayem, et al.
Published: (2022-10-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
by: Chan-Hee Jung, et al.
Published: (2019-03-01)

Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
by: Yoshimi Muta, et al.
Published: (2024-03-01)

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
by: Jack Alistair Sargeant, et al.
Published: (2019-09-01)

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis
by: Mengdie Hu, et al.
Published: (2020-04-01)

Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (sglt2) inhibitors
by: Hadeel Alfahmi, et al.
Published: (2017-01-01)

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
by: Minji Sohn, et al.
Published: (2023-06-01)

Glucagon-like peptide 2 (GLP-2) in bovine colostrum and transition milk
by: Yudai Inabu, et al.
Published: (2021-05-01)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
by: Jimmy Gonzalez, et al.
Published: (2023-03-01)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
by: Mohammed Aldhaeefi, et al.
Published: (2023-03-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01)

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
by: Yao Hao Teo, et al.
Published: (2021-03-01)

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
by: David Tak Wai Lui, et al.
Published: (2023-02-01)

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
by: Yi-Hsin Chan, et al.
Published: (2022-06-01)

Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
by: Vaia Lambadiari, et al.
Published: (2021-08-01)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment
by: Ignatios Ikonomidis, et al.
Published: (2020-05-01)

K+/Cl− cotransporter 2 (KCC2) and Na+/HCO3− cotransporter 1 (NBCe1) interaction modulates profile of KCC2 phosphorylation
by: Abhishek Pethe, et al.
Published: (2023-10-01)

Stathmin-2 Mediates Glucagon Secretion From Pancreatic α-Cells
by: Farzad Asadi, et al.
Published: (2020-02-01)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
by: Anzhu Wang, et al.
Published: (2022-05-01)

Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)
by: Ebaa Al-Ozairi, et al.
Published: (2024-02-01)

Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate
by: Kayla Chonko, et al.
Published: (2023-06-01)

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
by: Yen-Chieh Lee, et al.
Published: (2022-09-01)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
by: Mei Qiu, et al.
Published: (2021-12-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis
by: Mobin Mohammadtabar, et al.
Published: (2023-03-01)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto′s thyroiditis
by: Yue Jin, et al.
Published: (2015-01-01)

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans
by: Heeyoung Chae, et al.
Published: (2020-12-01)

Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
by: Jaime A Davidson, et al.
Published: (2023-02-01)

SGLT2 Inhibitors as Potential Anticancer Agents
by: Debasish Basak, et al.
Published: (2023-06-01)